WO2005049845A3 - Oncolytic herpes simplex virus encoding a heterologous nitroreductase - Google Patents

Oncolytic herpes simplex virus encoding a heterologous nitroreductase Download PDF

Info

Publication number
WO2005049845A3
WO2005049845A3 PCT/GB2004/004851 GB2004004851W WO2005049845A3 WO 2005049845 A3 WO2005049845 A3 WO 2005049845A3 GB 2004004851 W GB2004004851 W GB 2004004851W WO 2005049845 A3 WO2005049845 A3 WO 2005049845A3
Authority
WO
WIPO (PCT)
Prior art keywords
herpes simplex
simplex virus
nitroreductase
heterologous
virus encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/004851
Other languages
French (fr)
Other versions
WO2005049845A9 (en
WO2005049845A2 (en
Inventor
Susanne Moira Brown
Paul Dunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crusade Laboratories Ltd
Original Assignee
Crusade Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crusade Laboratories Ltd filed Critical Crusade Laboratories Ltd
Priority to JP2006538966A priority Critical patent/JP2007511215A/en
Priority to EP04798569A priority patent/EP1685254B1/en
Priority to DE602004021496T priority patent/DE602004021496D1/en
Priority to AT04798569T priority patent/ATE433493T1/en
Priority to US10/579,606 priority patent/US7498161B2/en
Publication of WO2005049845A2 publication Critical patent/WO2005049845A2/en
Publication of WO2005049845A3 publication Critical patent/WO2005049845A3/en
Anticipated expiration legal-status Critical
Publication of WO2005049845A9 publication Critical patent/WO2005049845A9/en
Priority to US12/065,350 priority patent/US7897146B2/en
Priority to US12/357,123 priority patent/US20090208460A1/en
Priority to US13/005,387 priority patent/US20110158948A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy.
PCT/GB2004/004851 2003-11-17 2004-11-17 Oncolytic herpes simplex virus encoding a heterologous nitroreductase Ceased WO2005049845A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2006538966A JP2007511215A (en) 2003-11-17 2004-11-17 Virus mutant
EP04798569A EP1685254B1 (en) 2003-11-17 2004-11-17 Oncolytic herpes simplex virus encoding a heterologous nitroreductase
DE602004021496T DE602004021496D1 (en) 2003-11-17 2004-11-17 FOR ONE HETEROLOGIC NITROREDUCTASE-CODING ONCOLYTIC HERPES SIMPLEX VIRUS
AT04798569T ATE433493T1 (en) 2003-11-17 2004-11-17 ONCOLYTIC HERPES SIMPLEX VIRUS ENCODING A HETEROLOGUE NITROREDUCTASE
US10/579,606 US7498161B2 (en) 2003-11-17 2004-11-17 Mutant herpes simplex viruses comprising nucleic acid encoding a nitroreductase
US12/065,350 US7897146B2 (en) 2003-11-17 2006-08-30 Treatment using herpes simplex virus
US12/357,123 US20090208460A1 (en) 2003-11-17 2009-01-21 Mutant Herpes Simplex Viruses Comprising Nucleic Acid Encoding A Nitroreductase
US13/005,387 US20110158948A1 (en) 2003-11-17 2011-01-12 Treatment Using Herpes Simplex Virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326798.6A GB0326798D0 (en) 2003-11-17 2003-11-17 Methods for generating mutant virus
GB0326798.6 2003-11-17

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US10/579,606 A-371-Of-International US7498161B2 (en) 2003-11-17 2004-11-17 Mutant herpes simplex viruses comprising nucleic acid encoding a nitroreductase
PCT/GB2006/003215 Continuation-In-Part WO2007026146A1 (en) 2003-11-17 2006-08-30 Treatment using herpes simplex virus
US12/065,350 Continuation-In-Part US7897146B2 (en) 2003-11-17 2006-08-30 Treatment using herpes simplex virus
US12065350 Continuation-In-Part 2008-04-18
US12/357,123 Continuation US20090208460A1 (en) 2003-11-17 2009-01-21 Mutant Herpes Simplex Viruses Comprising Nucleic Acid Encoding A Nitroreductase

Publications (3)

Publication Number Publication Date
WO2005049845A2 WO2005049845A2 (en) 2005-06-02
WO2005049845A3 true WO2005049845A3 (en) 2005-10-27
WO2005049845A9 WO2005049845A9 (en) 2006-08-17

Family

ID=29763982

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2004/004839 Ceased WO2005049844A2 (en) 2003-11-17 2004-11-17 Vectors, mutant viruses and methods for generating mutant viruses
PCT/GB2004/004851 Ceased WO2005049845A2 (en) 2003-11-17 2004-11-17 Oncolytic herpes simplex virus encoding a heterologous nitroreductase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004839 Ceased WO2005049844A2 (en) 2003-11-17 2004-11-17 Vectors, mutant viruses and methods for generating mutant viruses

Country Status (7)

Country Link
US (3) US20070110720A1 (en)
EP (3) EP2281897A3 (en)
JP (1) JP2007511215A (en)
AT (2) ATE433493T1 (en)
DE (2) DE602004029608D1 (en)
GB (1) GB0326798D0 (en)
WO (2) WO2005049844A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
WO2007026146A1 (en) * 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
WO2005049846A2 (en) 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
GB0409596D0 (en) * 2004-04-29 2004-06-02 Crusade Lab Ltd Novel herpes simplex viruses and uses thereof
EP2114420B1 (en) 2007-02-16 2016-01-27 Virttu Biologics Limited Herpes simplex viruses and methods of viral replication
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses
US8334097B2 (en) * 2009-05-01 2012-12-18 Vivebio, Llc Method of pooling and/or concentrating biological specimens for analysis
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
US10357577B2 (en) 2010-07-16 2019-07-23 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
WO2012071276A1 (en) * 2010-11-23 2012-05-31 Xiaoliu Zhang Oncolytic virus as an inducer for innate antitumor immunity
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
EP2662117A1 (en) 2012-05-11 2013-11-13 Virttu Biologics Limited Herpes Simplex Virus for the treatment of liver cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
ES2753391T3 (en) 2014-10-14 2020-04-08 Halozyme Inc Adenosine deaminase 2 (ADA2) compositions, variants thereof and methods of use thereof
IL262365B2 (en) 2016-04-15 2024-11-01 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
EP4706777A2 (en) 2016-04-15 2026-03-11 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
CN110088127A (en) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 CD155 variant immune modulator and application thereof
CA3040296A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
JP2020501589A (en) 2016-12-23 2020-01-23 ウイルツ・バイオロジクス・リミテッド Cancer treatment
CN110546265A (en) 2017-02-09 2019-12-06 因达普塔治疗公司 Engineered natural killer (NK) cells and compositions and methods thereof
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
PT3596116T (en) 2017-03-16 2023-12-04 Alpine Immune Sciences Inc Pd-l1 variant immunomodulatory proteins and uses thereof
JP2020511144A (en) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド PD-L2 variant immunomodulatory proteins and uses thereof
SMT202600062T1 (en) 2017-10-18 2026-03-09 Alpine Immune Sciences Inc Variant icos ligand immunomodulatory proteins and related compositions and methods
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CN110117577B (en) * 2018-02-05 2023-10-24 中国科学院武汉物理与数学研究所 Low-toxicity herpes simplex virus system and construction method and application thereof
IL278294B2 (en) 2018-05-01 2025-01-01 Albert Einstein College Medicine HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE
KR102662837B1 (en) 2018-06-04 2024-05-03 카리디 바이오테라퓨틱스, 인크. Cell-Based Vehicles for Enhancement of Viral Therapeutics
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3876951A1 (en) 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods
TW202038947A (en) 2018-11-28 2020-11-01 德商創新分子有限責任公司 Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CN113748124A (en) 2019-02-27 2021-12-03 阿克蒂姆治疗有限公司 Immunostimulatory bacteria engineered to colonize tumors, tumor resident immune cells, and tumor microenvironment
KR20230088306A (en) 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 Natural Killer (NK) Cell Compositions and Methods of Producing The Same
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
LT7046B (en) 2022-04-15 2024-02-12 Vilniaus Universitetas Hydrolases and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055345A1 (en) * 1998-04-30 1999-11-04 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
WO2003018788A2 (en) * 2001-08-21 2003-03-06 Ml Laboratories Plc Improved nitroreductase enzymes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
DE68912441T2 (en) 1988-06-24 1994-05-11 British Tech Group Nonessential chickenpox virus regions.
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
EP1380651A2 (en) 1991-08-26 2004-01-14 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
CA2122036C (en) * 1991-10-23 2002-09-17 Gillian Anlezark Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form
DE4228458A1 (en) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronic expression units and their use
WO1995004139A1 (en) 1993-07-27 1995-02-09 The Wistar Institute Of Anatomy And Biology Modified dna virus vectors and uses therefor
AT403167B (en) * 1994-11-14 1997-11-25 Immuno Ag SELECTION AND EXPRESSION OF FOREIGN PROTEINS BY MEANS OF A SELECTION-AMPLIFICATION SYSTEM
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
ZA966287B (en) 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
CA2234877A1 (en) 1995-10-19 1997-04-24 St. Jude Children's Research Hospital Herpesvirus vectors and their uses
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
WO2000034497A2 (en) 1998-12-09 2000-06-15 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
CA2383372C (en) 1999-08-31 2010-04-13 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
EP1111061A1 (en) * 1999-12-20 2001-06-27 Universite Libre De Bruxelles Double selection vector
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
DE60115600T2 (en) * 2000-01-21 2006-07-20 Biovex Ltd. VIRUSES FOR ONCOLYTIC TREATMENT OF CANCER
CA2452653A1 (en) * 2001-07-17 2003-01-30 Anne Josephine Milner Silencing of gene expression by sirna
US7348418B2 (en) 2002-02-08 2008-03-25 Memorial Sloan-Kettering Cancer Center Carcinoma-related genes and polypeptides and methods of use thereof
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
AU2003216502B2 (en) * 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
US7288529B2 (en) * 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055345A1 (en) * 1998-04-30 1999-11-04 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
WO2003018788A2 (en) * 2001-08-21 2003-03-06 Ml Laboratories Plc Improved nitroreductase enzymes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIU B L ET AL: "ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.", GENE THERAPY, vol. 10, no. 4, February 2003 (2003-02-01), pages 292 - 303, XP002313120, ISSN: 0969-7128 *
MCNEISH I A ET AL: "VIRUS DIRECTED ENZYME PRODRUG THERAPY FOR OVARIAN AND PANCREATIC CANCER USING RETROVIRALLY DELIVERED E. COLI NITROREDUCTASE AND CB1954", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 5, no. 8, August 1998 (1998-08-01), pages 1061 - 1069, XP000901446, ISSN: 0969-7128 *
VARGHESE SUSAN ET AL: "Oncolytic herpes simplex virus vectors for cancer virotherapy.", CANCER GENE THERAPY, vol. 9, no. 12, December 2002 (2002-12-01), pages 967 - 978, XP002313119, ISSN: 0929-1903 *
WEEDON S J ET AL: "SENSITISATION OF HUMAN CARCINOMA CELLS TO THE PRODRUG CB1954 BY ADENOVIRUS VECTOR-MEDIATED EXPRESSION OF E. COLI NITROREDUCTASE", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 86, no. 6, 15 June 2000 (2000-06-15), pages 848 - 854, XP001015211, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
DE602004021496D1 (en) 2009-07-23
US20090208460A1 (en) 2009-08-20
ATE484596T1 (en) 2010-10-15
EP1685254B1 (en) 2009-06-10
US20070110720A1 (en) 2007-05-17
EP2281897A3 (en) 2011-11-30
DE602004029608D1 (en) 2010-11-25
JP2007511215A (en) 2007-05-10
WO2005049844A2 (en) 2005-06-02
US20070098689A1 (en) 2007-05-03
GB0326798D0 (en) 2003-12-24
WO2005049845A9 (en) 2006-08-17
WO2005049844A3 (en) 2005-10-20
EP2281897A2 (en) 2011-02-09
ATE433493T1 (en) 2009-06-15
US7498161B2 (en) 2009-03-03
WO2005049845A2 (en) 2005-06-02
EP1692294A2 (en) 2006-08-23
EP1685254A2 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
WO2005049845A3 (en) Oncolytic herpes simplex virus encoding a heterologous nitroreductase
WO2008108890A3 (en) Conditionally replicating viruses for cancer therapy
WO2008099189A3 (en) Herpes simplex viruses and methods of viral replication
WO2006096815A3 (en) NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES
WO2005049846A3 (en) Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
WO2010136981A3 (en) Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
WO2004037977A3 (en) Use of chimeric nucleases to stimulate gene targeting
WO2001053506A3 (en) Virus strains for the oncolytic treatment of cancer
WO2005118825A3 (en) Chimeric adenoviruses for use in cancer treatment
WO2003085110A3 (en) Oligomeric compounds for the modulation hif-1alpha expression
WO2002101057A1 (en) Gene transfer into primate embryonic stem cells using vsv-g pseudo type simian immunodeficiency virus vector
EP1505154A4 (en) Vectors with modified protease-dependent tropism
WO2006012221A3 (en) Target cell-specific short interfering rna and methods of use thereof
AU2003284689A8 (en) Nucleic acid construct containing hepatitis c virus (hcv) of genocype 2a genome-origin nucleic acid and cell having the nucleic acid construct transferred thereinto
KR100469936B1 (en) Cell surface expression vector of SARS virus antigen and microorganism transformed by the vector
WO2003015708A8 (en) Composition and method for treating hiv infection
WO2006078284A3 (en) Methods and compositions related to antiviral therapy using algae and cyanobacteria
AU2003279240A1 (en) Methods for purifying viral particles for gene therapy
WO2004024940A3 (en) Rna-mediated gene modulation
EP1712243A4 (en) Gene therapy for tumor using minus-strand rna viral vectors encoding immunostimulatory cytokines
AU2002347813A1 (en) Chimeric viral vectors for gene therapy
AU2003215161A1 (en) RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003053332A3 (en) Composition and method for treating viral infection
AU2002352195A1 (en) Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors
AU2003213057A1 (en) Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006538966

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007098689

Country of ref document: US

Ref document number: 10579606

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004798569

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004798569

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10579606

Country of ref document: US